Urgent.News

What's breaking now, across thousands of outlets.

Science

Vitamin B12 may hold the key to treating a rare genetic disorder

Scientists discovered that vitamin B12 largely reversed developmental abnormalities in worms carrying a genetic mutation linked to Verheij syndrome, a rare disorder that causes growth problems and developmental delays. Similar metabolic changes were identified in human patients, raising the possibility that this common vitamin could inspire new treatments for rare genetic diseases.

A groundbreaking discovery involving vitamin B12 could potentially revolutionize the treatment of rare genetic disorders. Researchers have found that this essential nutrient can rectify developmental issues in tiny worms carrying a genetic mutation linked to Verheij syndrome, a human condition characterized by developmental delays, stunted growth, and short stature.

This revelation sheds light on the crucial role of RNA splicing, a cellular process that prepares genetic instructions for protein production. When splicing goes awry, it can disrupt normal cellular functions and lead to severe developmental disorders. The scientists arrived at this discovery by studying C. elegans, a common laboratory model, and examining a mutation in a gene responsible for RNA splicing, which is also associated with Verheij syndrome in humans.

Worms with the mutation exhibited slowed growth and remained smaller than their counterparts. Further investigation revealed that the mutation interfered with specific metabolic pathways reliant on vitamin B12, essential for healthy growth and cellular activity. Providing additional vitamin B12 reversed these changes, restoring normal metabolic processes and correcting the developmental abnormalities in the worm model.

While the findings are promising, researchers have not yet confirmed whether vitamin B12 supplementation can alleviate symptoms in humans with Verheij syndrome. Further studies are required to determine if the observed benefits can be translated into a viable treatment for patients. This discovery also highlights the potential for metabolic disruptions to contribute significantly to diseases caused by faulty RNA splicing, a phenomenon previously underestimated.

Understanding these connections may lead to the identification of novel therapeutic strategies, extending beyond Verheij syndrome to other rare genetic conditions. As Adam Antebi, Director at the Max Planck Institute for Biology of Ageing and lead author of the study, aptly notes, "Our study exemplifies how fundamental research on model organisms can yield insights into human diseases, potentially paving the way for innovative medical approaches."

Written by urgent.news from ScienceDaily's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at sciencedaily.com →

More in Science

More from Monday 16 November →